// App-Quantinova.ai

P343 : Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study

Researchers

Presenter

  • W J Sandborn

Principal Investigators

  • B Sands

  • J-F Colombel

  • C Gasink

  • R Patel

  • D Jacobstein

  • L-L Gao

  • S Ghosh

  • S Targan

  • W De Villiers

  • S B Hanauer

  • P Rutgeerts

  • B Feagan

Medical Centers

  • University of California, San Diego, La Jolla, CA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Janssen Scientific Affairs, Horsham, PA

  • Jannsen Pharmaceuticals, Horsham, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • University of Birmingham, Birmingham, United Kingdom

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Stellenbosch University, Stellenbosch, South Africa

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada

Locations

  • United States

  • United Kingdom

  • South Africa

  • Belgium

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved